TRUQAP
Jun 25, 2024
AstraZeneca’s AKT Inhibitor TRUQAP Falls Short in Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) constitutes about 10-15% of all breast cancer cases with nearly 44,000 incident cases in the United States in 2023, as per Delveinsight’s estimates. It is a rare but aggressive form of breast cancer. Treatment for TNBC is more limited than for other breast cancer types. C...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
